Abstract 5MO
Background
While numerous studies have consistently reported that the molecular subtypes of breast cancer are associated with different patterns of distant metastasis, few studies have investigated the impact of molecular subtypes on loco-regional recurrence. We retrospectively investigated the patterns of loco-regional recurrence in a large cohort.
Methods
We reviewed the clinical records of all patients who underwent breast cancer surgery between January 2000 and December 2018 in a single institution and investigated the ipsilateral breast cancer recurrence (IBTR), regional recurrence (RR), and contralateral breast cancer (CBC) events. Tumor subtypes were sub-grouped according to hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) status.
Results
A total of 16,462 patients were included in the analysis. For all patients, the ten-year IBTR-, RR- and CBC survival rate was 4.1%, 3.9% and 3.5%, respectively. On the log-rank test, HR-/HER+ tumors showed the worst IBTR-free survival rate (p<0.001), while HR-/HER2- subtype showed the worst RR- and CBC-free survival rate among all subtypes (p<0.001). Regarding annual recurrence patterns, the IBTR pattern of HR-/HER2+ and HR-/HER- subtypes showed double-peaks, while HR+/HER2- tumors showed a steadily increasing pattern without distinguishable peaks. Additionally, the HR+/HER2- subtype seems to have a steady RR pattern, while other subtypes showed the highest RR incidence at one year following surgery before gradually decreasing. Lastly, the annual recurrence rate of CBC showed gradually increasing tendencies for all subtypes, and the HR-/HER2- subtype showed a highest CBC rate for ten years. Younger patients had more evident difference in IBTR, RR, and CBC pattern between subtypes than elderly.
Conclusions
Loco-regional recurrence occurs with different patterns according to BC subtypes. The guidelines should consider the difference in loco-regional recurrence patterns according to tumor subtypes and recommend tailored surveillance strategies, especially for young patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
W. Han, H. Lee: Non-Financial Interests, Personal, Stocks/Shares: DCGen. All other authors have declared no conflicts of interest.
Resources from the same session
1MO - The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study
Presenter: Zhimin Shao
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
2MO - Final analysis of the phase III randomized clinical trial, comparing HD201 vs referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting
Presenter: Xavier Pivot
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 1MO and 2MO
Presenter: Ching-Hung Lin
Session: Mini Oral session: Breast cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Khalil Zaman
Session: Mini Oral session: Breast cancer
Resources:
Slides
Webcast
3MO - Patient-reported outcomes (PROs) of Chinese patients (pts) in monarchE: Abemaciclib plus endocrine therapy (ET) in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)
Presenter: Qingyuan Zhang
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
21MO - Primary results of a China bridging, phase II randomized study of initial endocrine therapy (ET) ± ribociclib (RIB) in pre- & postmenopausal Chinese women with HR+/HER2– ABC
Presenter: Zhimin Shao
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
22MO - Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial
Presenter: Fei Ma
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 3MO, 21MO and 22MO
Presenter: Soo Chin Lee
Session: Mini Oral session: Breast cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Khalil Zaman
Session: Mini Oral session: Breast cancer
Resources:
Slides
Webcast
4MO - Prognostic implication of 21-gene expression assay in luminal B type hormone receptor-positive breast cancer patients younger than 40 years
Presenter: Jaewon Hyung
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast